Stockscreener 앱 받기
66.54
3.11%
2.01
시장 영업 전:
66.01
-0.53
-0.80%
전일 마감가:
$64.53
열려 있는:
$65
하루 거래량:
2.38M
Relative Volume:
0.89
시가총액:
$12.90B
수익:
$353.78M
순이익/손실:
$-805.69M
주가수익비율:
-15.89
EPS:
-4.1869
순현금흐름:
$-597.61M
1주 성능:
+0.00%
1개월 성능:
-11.50%
6개월 성능:
+28.38%
1년 성능:
+98.39%
1일 변동 폭
$64.25
$67.20
1주일 범위
$62.77
$68.47
52주 변동 폭
$28.32
$84.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
명칭
Bridgebio Pharma Inc
전화
(650) 391-9740
주소
3160 PORTER DR., PALO ALTO, CA
Compare BBIO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
66.54 | 12.51B | 353.78M | -805.69M | -597.61M | -4.1869 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2026-01-06 | 개시 | Morgan Stanley | Overweight |
| 2025-12-11 | 개시 | Bernstein | Outperform |
| 2025-07-30 | 재개 | Raymond James | Outperform |
| 2025-07-21 | 개시 | Truist | Buy |
| 2025-07-14 | 개시 | Jefferies | Buy |
| 2025-07-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-06-17 | 개시 | Wolfe Research | Outperform |
| 2025-03-31 | 개시 | Redburn Atlantic | Buy |
| 2024-10-16 | 개시 | Scotiabank | Sector Outperform |
| 2024-10-03 | 개시 | Oppenheimer | Perform |
| 2024-09-04 | 개시 | Piper Sandler | Overweight |
| 2024-03-21 | 재개 | Raymond James | Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Market Perform |
| 2023-12-08 | 개시 | Wells Fargo | Overweight |
| 2023-11-07 | 개시 | Citigroup | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-07-18 | 다운그레이드 | Jefferies | Buy → Hold |
| 2023-04-19 | 개시 | Evercore ISI | Outperform |
| 2023-02-06 | 개시 | Cowen | Outperform |
| 2021-12-27 | 재확인 | Mizuho | Buy |
| 2021-12-27 | 재확인 | SVB Leerink | Outperform |
| 2021-09-10 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2021-05-21 | 개시 | UBS | Buy |
| 2021-03-22 | 재확인 | Goldman | Buy |
| 2021-02-22 | 재개 | JP Morgan | Overweight |
| 2021-02-09 | 재개 | Goldman | Buy |
| 2021-01-11 | 재확인 | H.C. Wainwright | Buy |
| 2020-12-10 | 재확인 | H.C. Wainwright | Buy |
| 2020-06-25 | 개시 | BofA/Merrill | Neutral |
| 2020-05-19 | 개시 | BTIG Research | Buy |
| 2020-04-13 | 개시 | H.C. Wainwright | Buy |
| 2020-02-19 | 개시 | Mizuho | Buy |
| 2019-07-26 | 개시 | Raymond James | Outperform |
| 2019-07-22 | 개시 | BMO Capital Markets | Outperform |
| 2019-07-22 | 개시 | Goldman | Buy |
| 2019-07-22 | 개시 | JP Morgan | Overweight |
| 2019-07-22 | 개시 | Jefferies | Buy |
| 2019-07-22 | 개시 | Piper Jaffray | Overweight |
| 2019-07-22 | 개시 | SVB Leerink | Outperform |
모두보기
Bridgebio Pharma Inc 주식(BBIO)의 최신 뉴스
BridgeBio Pharma to Present Phase 3 FORTIFY Trial Data on LGMD2I/R9 Therapy at 2026 MDA Conference - geneonline.com
BridgeBio to present LGMD2I/R9 trial data at MDA conference By Investing.com - Investing.com Australia
[144] BridgeBio Pharma, Inc. SEC Filing - Stock Titan
BridgeBio to present LGMD2I/R9 trial data at MDA conference - Investing.com Nigeria
TD Asset Management Inc Purchases Shares of 88,950 BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma, Inc. (BBIO) Latest Stock News & Headlines - Yahoo Finance
BridgeBio Pharma to Present New Data on BBP-418 for LGMD2I/R9 at MDA Conference - Quiver Quantitative
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference - The Manila Times
BridgeBio muscular dystrophy trial hits key goals in Phase 3 study - Stock Titan
Aisling Capital Management LP Has $316.29 Million Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma Director Sells Shares - TradingView
BridgeBio (BBIO) director sells 25,484 shares after option exercise - Stock Titan
BBIO Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Rafferty Asset Management LLC Sells 44,792 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
BridgeBio Pharma (BBIO) Achieves Record 2025 Revenue Driven by Attruby Commercial Success - Bitget
Intech Investment Management Trims BridgeBio Pharma Stake - National Today
BridgeBio Pharma, Inc. (BBIO) Stock Analysis: Unpacking a 50.49% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Intech Investment Management LLC Sells 19,826 Shares of BridgeBio Pharma, Inc. $BBIO - MarketBeat
Is BridgeBio Pharma (BBIO) Attractive After Recent Pullback And Late Stage Pipeline Progress? - Yahoo Finance
Okabena Investment Services Inc. Makes New $816,000 Investment in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Monashee Investment Management LLC Lowers Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
ETFs investiert in BridgeBio Pharma, Inc.-Aktien - TradingView
Fox Run Management L.L.C. Reduces Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Insider Sell: Maricel Apuli Sells 2,000 Shares of BridgeBio Phar - GuruFocus
What BridgeBio Pharma (BBIO)'s Surging 2025 Revenue and Growing Losses Means For Shareholders - simplywall.st
BridgeBio (BBIO) CAO sells 2,000 shares in Rule 10b5-1 trade - Stock Titan
Analysts Offer Insights on Healthcare Companies: Tempus AI, Inc. Class A (TEM), BridgeBio Pharma (BBIO) and Establishment Labs Holdings (ESTA) - The Globe and Mail
BridgeBio Pharma Earnings Call Signals Profitable Pivot - TipRanks
BridgeBio Pharma (BBIO) Analyst Rating Update: Oppenheimer Lowers Price Target | BBIO Stock News - GuruFocus
BridgeBio Pharma (NASDAQ:BBIO) Trading Down 6.7% on Disappointing Earnings - MarketBeat
BridgeBio Pharma (BBIO): Today's Analyst Rating Update | BBIO St - GuruFocus
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $95.00 at Truist Financial - MarketBeat
Oppenheimer Issues Pessimistic Forecast for BridgeBio Pharma (NASDAQ:BBIO) Stock Price - MarketBeat
BridgeBio Pharma (BBIO) Receives Analyst Rating and Price Target Update | BBIO Stock News - GuruFocus
Morgan Stanley Forecasts Strong Price Appreciation for BridgeBio Pharma (NASDAQ:BBIO) Stock - MarketBeat
BridgeBio Pharma (BBIO): Evercore ISI Group Raises Price Target to $125 | BBIO Stock News - GuruFocus
Oppenheimer Adjusts Price Target on BridgeBio Pharma to $81 From $83, Maintains Outperform Rating - marketscreener.com
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Q4 2025 Earnings Call Transcript - Insider Monkey
BridgeBio Pharma: Clear Path to 2027 Profitability with Underappreciated Pipeline Upside - TipRanks
BridgeBio Pharma Reports Narrower Net Loss For Q4, Revenue Zooms On Attruby Sales - RTTNews
BridgeBio Pharma Inc (BBIO) Q4 2025 Earnings Call Highlights: St - GuruFocus
BridgeBio Pharma earnings missed by $0.28, revenue topped estimates - Investing.com Australia
Decoding BridgeBio Pharma Inc (BBIO): A Strategic SWOT Insight - GuruFocus
BridgeBio Pharma (BBIO) Projects Strong Cash Flow by 2028 - GuruFocus
BridgeBio Pharma, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
BridgeBio Pharma (BBIO) Reports Q4 Loss, Beats Revenue Estimates - Nasdaq
BridgeBio (BBIO) Q4 2025 Earnings Call Transcript - AOL.com
BridgeBio Pharma Q4 Earnings Call Highlights - MarketBeat
BridgeBio rises on revenue beat despite wider loss - Investing.com South Africa
BridgeBio (BBIO) Exceeds Revenue Expectations in Q4 - GuruFocus
BridgeBio Pharma (NASDAQ: BBIO) grows ATTR franchise and advances three Phase 3 drugs - Stock Titan
Bridgebio Pharma Inc (BBIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Bridgebio Pharma Inc 주식 (BBIO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Valantine Hannah | Director |
Feb 27 '26 |
Option Exercise |
48.45 |
25,484 |
1,234,700 |
32,949 |
| Valantine Hannah | Director |
Feb 27 '26 |
Sale |
67.41 |
25,484 |
1,717,781 |
7,465 |
0.11%
6.00%
자본화:
|
볼륨(24시간):